Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (49)

« Back to Publications

Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.

Yang H. et al, (2021), Cell reports, 35

HLA-E-restricted, Gag-specific CD8+ T cells can suppress HIV-1 infection, offering vaccine opportunities.

Yang H. et al, (2021), Science immunology, 6

Lessons from the Research in Viral Eradication of Reservoirs (RIVER) study: Impact of a therapeutic vaccine targeting conserved HIV epitopes on T cell function in treated primary infection

Kopycinski J. et al, (2019), JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 22, 20 - 21

Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).

Mothe B. et al, (2019), EClinicalMedicine, 11, 65 - 80

Oral abstracts of the 22nd International AIDS Conference, 23-27 July 2018, Amsterdam, the Netherlands.

(2018), Journal of the International AIDS Society, 21 Suppl 6

Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction.

Yang H. et al, (2018), Frontiers in immunology, 9

Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.

Hancock G. et al, (2017), Journal of the International AIDS Society, 20

Engineered affinity-enhanced immune-mobilising monoclonal T cell receptors (ImmTAVs) for HIV cure

Wallace Z. et al, (2017), HIV MEDICINE, 18, 7 - 7

Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.

Yang H. et al, (2016), Molecular therapy : the journal of the American Society of Gene Therapy, 24, 1913 - 1925

Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells.

Ternette N. et al, (2016), European journal of immunology, 46, 60 - 69

Aviremia 10 Years Postdiscontinuation of Antiretroviral Therapy Initiated During Primary Human Immunodeficiency Virus-1 Infection and Association With Gag-Specific T-Cell Responses.

Kinloch-de Loes S. et al, (2015), Open Forum Infectious Diseases, 2

Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses.

Hancock G. et al, (2015), PLoS pathogens, 11

Engineered Gag-specific T-cell Receptors Redirect Polyclonal CD8(+) T-cells to Clear HIV-1-infected CD4(+) T-cells from ART-treated Patients.

Yang H. et al, (2014), AIDS research and human retroviruses, 30 Suppl 1

Evaluation of the Immunogenicity and Impact on the Latent HIV-1 Reservoir of an HIV Conserved Region Vaccine, MVA.HIVconsv, in HAART-treated Subjects

Morón-López S. et al, (2014), AIDS Research and Human Retroviruses, 30, A190 - A190

Emergence of a distinct HIV-specific IL-10-producing CD8+ T-cell subset with immunomodulatory functions during chronic HIV-1 infection.

Clutton G. et al, (2013), European journal of immunology, 43, 2875 - 2885

Load More